Progenra, Inc.
Dedicated to finding new medicines for a variety of diseases through the ubiquitin pathway, a critical mechanism of cellular regulation. Progenra's assay platform and unique profiling capacity can identify selective inhibitors of critical ubiquitin pathway enzymes associated with cancer, osteoporosis, and other debilitating diseases. This technology and multiple selective compounds are available for licensing.
Novel Science
Progenra’s goal is to discover novel drugs targeting the ubiquitin pathway using their proprietary technology.
DEUBIQUITYLASE TECHNOLOGY
E3 LIGASE TECHNOLOGY
Upcoming Meetings
Progenra Headlines
Date: 11.23.11
New Study Demonstrating the Intracellular Selectivity of Progenra's Novel Anti-Tumor Compound
Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled “Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes” (Altun et al, Chemistry & Biology, Volume 18, Issue 11, 1401-1412, 23 November 2011) that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).
Business Development
Progenra wishes to partner with academic and commercial entities to further promote the distribution and use of its HTS technologies